Possible roles of insulin signaling in osteoblasts

Endocrine Research

Volumn 39, Issue 4, 2014, Pages 144-151

  Pramojanee, Sakarat N ^a   Phimphilai, Mattabhorn ^b   Chattipakorn, Nipon ^a   Chattipakorn, Siriporn C ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Energy metabolism; Insulin receptor; Insulin signaling pathway; Osteoblasts; Undercarboxylated osteocalcin

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN SH2; SOMATOMEDIN C; TYROSINE KINASE RECEPTOR; INSR PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

BONE DENSITY; BONE GROWTH; BONE MASS; BONE REMODELING; BONE TURNOVER; CALLUS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; ENERGY METABOLISM; GENE DELETION; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MEDIATOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; PHENOTYPIC VARIATION; PROTEIN PHOSPHORYLATION; REVIEW; TRABECULAR BONE; AGONISTS; ANIMAL; BONE DEVELOPMENT; COMPLICATION; DIABETES MELLITUS; METABOLIC BONE DISEASE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; BONE DISEASES, METABOLIC; DIABETES COMPLICATIONS; ENERGY METABOLISM; HUMANS; INSULIN; MAP KINASE SIGNALING SYSTEM; OSTEOBLASTS; OSTEOGENESIS; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84911478017     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2013.879168     Document Type: Review

References (73)

1. Banting FG, Best CH. Pancreatic extracts. 1922. J Lab Clin Med 1990;115:254-72.
2. Ituarte EA, Halstead LR, Iida-Klein A, et al. Glucose transport system in UMR-106-01 osteoblastic osteosarcoma cells: regulation by insulin. Calcif Tissue Int 1989;45:27-33.
3. Kream BE, Smith MD, Canalis E, Raisz LG. Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology 1985;116:296-302.
4. Pramojanee SN, Phimphilai M, Kumphune S, et al. Decreased jaw bone density and osteoblastic insulin signaling in a model of obesity. J Dent Res 2013;92:560-65.
5. Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res 1989;4:853-62.
6. Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem Funct 2010;28:334-41.
7. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 1996;59:492-5.
8. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99-109.
9. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
10. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1-4.
11. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005;45:828-33.
12. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002;283:E413-22.
13. Sesti G, Federici M, Hribal ML, et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001;15:2099-111.
14. Akune T, Ogata N, Hoshi K, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 2002;159:147-56.
15. Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004;27:361-70.
16. Ogata N, Chikazu D, Kubota N, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 2000;105:935-43.
17. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nature reviews 2006;7: 85-96.
18. Avruch J, Khokhlatchev A, Kyriakis JM, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001;56:127-55.
19. Lovicu FJ, McAvoy JW. FGF-induced lens cell proliferation and differentiation is dependent on MAPK (ERK1/2) signalling. Development 2001;128:5075-84.
20. Werner H, Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997;8:71-92.
21. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 1999;274:1865-8.
22. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998;333: 471-90.
23. Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005; 183:3-12.
24. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res 2008;79:238-48.
25. Zundel W, Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev 1998;12:1941-6.
26. Grey A, Chen Q, Xu X, et al. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 2003;144: 4886-93.
27. Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010;142: 296-308.
28. Thomas DM, Udagawa N, Hards DK, et al. Insulin receptor expression in primary and cultured osteoclast-like cells. Bone 1998; 23:181-6.
29. Kawamura N, Kugimiya F, Oshima Y, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PloS One 2007;2:e1058.
30. Wei J, Karsenty G. Bone as a site of insulin resistance in type 2 diabetes. BioMed Central Proceedings 2012. 74 p.
31. Rached MT, Kode A, Xu L, et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 2010;11:147-60.
32. Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010;142:309-19.
33. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002;277:44005-12.
34. Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-69.
35. Irwin R, Lin HV, Motyl KJ, McCabe LR. Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology 2006;147:5760-7.
36. Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007;40:345-53.
37. Ogawa N, Yamaguchi T, Yano S, et al. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucoseinduced increase in the receptor for AGEs. Horm Metab Res 2007; 39:871-5.
38. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005;65: 1013-5.
39. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev 2002;1: 769-83.
40. Fulzele K, DiGirolamo DJ, Liu Z, et al. Disruption of the insulinlike growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007;282:25649-58.
41. Bu YH, He YL, Zhou HD, et al. Insulin receptor substrate 1 regulates the cellular differentiation and the matrix metallopeptidase expression of preosteoblastic cells. J Endocrinol 2010;206: 271-7.
42. Shimoaka T, Kamekura S, Chikuda H, et al. Impairment of bone healing by insulin receptor substrate-1 deficiency. J Biol Chem 2004;279:15314-22.
43. Hoshi K, Ogata N, Shimoaka T, et al. Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage. J Bone Miner Res 2004;19:214-23.
44. Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182-6.
45. Xiao G, Jiang D, Thomas P, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 2000;275:4453-9.
46. Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci 2009;122:716-26.
47. Liu X, Bruxvoort KJ, Zylstra CR, et al. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 2007;104:2259-64.
48. Burguera B, Brunetto A, Garcia-Ocana A, et al. Leptin increases proliferation of human steosarcoma cells through activation of PI(3)-K and MAPK pathways. Med Sci Monit 2006;12:BR341-9.
49. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007;18:427-44.
50. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
51. Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diab Care 2008;31:S262-8.
52. Karimifar M, Pasha MA, Salari A, et al. Evaluation of bone loss in diabetic postmenopausal women. J Res Med Sci 2012;17:1033-8.
53. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48:1292-9.
54. de L II, van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mllitus: the Rotterdam Study. Osteoporos Int 2005;16:1713-20.
55. Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone? Diabetes Care 1996;19:1388-92.
56. Dennison EM, Syddall HE, Aihie Sayer A, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia 2004;47:1963-8.
57. Stolk RP, Van Daele PL, Pols HA, et al. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone 1996;18:545-9.
58. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007;102:1343-57.
59. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000;11: 455-9.
60. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004;19: 1084-91.
61. Yuksel O, Dokmetas HS, Topcu S, et al. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 2001;19:257-62.
62. Reid IR. Relationships between fat and bone. Osteoporos Int 2008; 19:595-606.
63. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-69.
64. Weinreb M, Shinar D, Rodan GA. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 1990; 5:831-42.
65. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 2011;26: 677-80.
66. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008;105:5266-70.
67. Hwang YC, Jeong IK, Ahn KJ, Chung HY. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int 2012;23: 1337-42.
68. Iki M, Tamaki J, Fujita Y, et al. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int 2012;23:761-70.
69. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:45-9.
70. Kanazawa I, Yamaguchi T, Yamauchi M, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011;22:187-94.
71. Ngarmukos C, Chailurkit LO, Chanprasertyothin S, et al. A reduced serum level of total osteocalcin in men predicts the development of diabetes in a long-term follow-up cohort. Clin Endocrinol 2012;77: 42-6.
72. Saleem U, Mosley Jr TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010;30:1474-8.
73. Yeap BB, Chubb SA, Flicker L, et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 2010;163:265-72.